ACC010 , a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ ITD
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Yu Qian und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: beta Catenin, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bromodomain‐containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β‐catenin pathway. Meanwhile, homoharringtonine (HHT), a classic antileukemia drug, possibly inhibits the WNT/β‐catenin pathway. In this study, we attempted to combine a novel BRD4 inhibitor (ACC010) and HHT to explore their synergistic lethal effects in treating AML. Here, we found that co‐treatment with ACC010 and HHT synergistically inhibited cell proliferation, induced apoptosis, and arrested the cell cycle in FMS‐like tyrosine kinase 3‐internal tandem duplication ( FLT3 ‐ITD)–positive AML cells in vitro , and significantly inhibiting AML progression in vivo . Mechanistically, ACC010 and HHT cooperatively downregulated MYC and inhibited FLT3 activation. Further, when HHT was added, ACC010‐resistant cells demonstrated a good synergy. We also extended our study to the mouse BaF3 cell line with FLT3‐inhibitor‐resistant FLT3 ‐ITD/tyrosine kinase domain mutations and AML cells without FLT3 ‐ITD. Collectively, our results suggested that the combination treatment of ACC010 and HHT might be a promising strategy for AML patients, especially those carrying FLT3 ‐ITD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.
- Zhejiang University Cancer Center, Hangzhou, China.
- The Affiliated People's Hospital of Ningbo University, China.
- Jinan Microecological Biomedicine Shandong Laboratory, China.
ORCID-Profile: Jie Jin
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qian, Y., Zhang, X., Mao, S., Wei, W., Lin, X., Ling, Q., Ye, W., Li, F., Pan, J., Zhou, Y., Zhao, Y., Huang, X., Huang, J., Tong, H., Sun, J., & Jin, J. (2023). ACC010 , a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ ITD. Molecular Oncology. https://doi.org/10.1002/1878-0261.13368
Vancouver
Qian Y, Zhang X, Mao S, Wei W, Lin X, Ling Q, et al. ACC010 , a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ ITD. Molecular Oncology. 2023. doi:10.1002/1878-0261.13368
BibTeX
@article{Qian2023,
author = {Qian, Yu and Zhang, Xiang and Mao, Shihui and Wei, Wenwen and Lin, Xiangjie and Ling, Qing and Ye, Wenle and Li, Fenglin and Pan, Jiajia and Zhou, Yutong and Zhao, Yanchun and Huang, Xin and Huang, Jiansong and Tong, Hongyan and Sun, Jie and Jin, Jie},
title = {ACC010 , a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ ITD},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13368}
}
EUVIMED